{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:12:36Z","timestamp":1790993556064,"version":"4.1.0"},"reference-count":70,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Vitiligo is a chronic autoimmune disorder characterized by CD8+ T cell-mediated destruction of melanocytes. It affects up to 2% of the global population and has a profound psychosocial impact. Over the past two decades, advances in understanding immunological mechanisms, particularly IFN-\u03b3 signaling and JAK-STAT pathway dysregulation, have reshaped therapeutic approaches from empirical regimens to targeted immunomodulatory interventions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To analyze global vitiligo treatment research trends from 2005 to 2025, examining publication patterns, collaboration networks, and the evolution of therapeutic strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Publications related to vitiligo treatment were retrieved from the Web of Science Core Collection (WoSCC) and analyzed using R (Bibliometrix), VOSviewer, and CiteSpace. Scopus database was used for supplementary validation of major trends. In parallel, randomized controlled trials (RCTs) were systematically identified from PubMed to contextualize clinical research.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 3, 483 publications were included in this study. Annual output increased at a compound growth rate of 7.27%. China, the United States, and India were the leading contributors, whereas the Egyptian Knowledge Bank and Harvard University were the most productive institutions. Thematic analysis revealed a gradual transition from traditional therapies such as corticosteroids and phototherapy to immune-targeted strategies. Citation bursts highlight the emergence of JAK inhibitors and biologics. Network analyses revealed fragmented author clusters, but strong international collaborations, particularly in Europe. An analysis of 249 RCTs revealed that pharmacological therapies, surgical interventions, and phototherapy constitute the three major research themes. Immunomodulatory therapies, particularly JAK inhibitors, such as ritlecitinib, have emerged as a key focus in ongoing clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This multi-database analysis delineates the evolving landscape of vitiligo treatment research, characterized by expanding output and increasing focus on immune-targeted therapies. Persistent gaps in clinical evidence, especially regarding long-term outcomes and pediatric populations, underscore the need for continued high-quality clinical studies in this field.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1733857","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T06:41:18Z","timestamp":1768372878000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["From immunological mechanisms to targeted therapies: a bibliometric analysis of vitiligo treatment research (2005\u20132025)"],"prefix":"10.3389","volume":"16","author":[{"given":"Longfei","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e0163806","DOI":"10.1371\/journal.pone.0163806","article-title":"The prevalence of vitiligo: A meta-analysis","volume":"11","author":"Zhang","year":"2016","journal-title":"PloS One"},{"key":"B2","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S0140-6736(14)60763-7","article-title":"Vitiligo","volume":"386","author":"Ezzedine","year":"2015","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.jaad.2017.02.049","article-title":"Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib","volume":"76","author":"Rothstein","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30609-7","article-title":"Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial","volume":"396","author":"Rosmarin","year":"2020","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00752-6","article-title":"Vitiligo treatments: review of current therapeutic modalities and JAK inhibitors","volume":"24","author":"Cunningham","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"B6","unstructured":"FDA approves topical treatment addressing repigmentation in vitiligo in patients aged 12 and older 2022 [updated 07\/19\/2022; cited 2025 September 10]"},{"key":"B7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.joi.2017.08.007","article-title":"bibliometrix: An R-tool for comprehensive science mapping analysis","volume":"11","author":"Aria","year":"2017","journal-title":"J Informetri"},{"key":"B9","doi-asserted-by":"publisher","first-page":"365","DOI":"10.4103\/ijd.ijd_673_23","article-title":"100 most-cited articles in vitiligo: A bibliometric analysis","volume":"69","author":"Attal","year":"2024","journal-title":"Indian J Dermatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e2024239","DOI":"10.5826\/dpc.1404a239","article-title":"Knowledge structure and trends of vitiligo from 2002 to 2023: A bibliometric analysis","volume":"14","author":"Wen","year":"2024","journal-title":"Dermatol Pract Concept"},{"key":"B11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.5195\/jmla.2019.433","article-title":"Exploring PubMed as a reliable resource for scholarly communications services","volume":"107","author":"Ossom Williamson","year":"2019","journal-title":"J Med Libr Assoc"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.5195\/jmla.2024.1669","article-title":"Understanding the performance of geographic limits on Web of Science Core Collection databases, using the United Kingdom as an example","volume":"112","author":"Fulbright","year":"2024","journal-title":"J Med Libr Assoc"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s11192-021-03948-5","article-title":"The journal coverage of Web of Science, Scopus and Dimensions: A comparative analysis","volume":"126","author":"Singh","year":"2021","journal-title":"Scientometrics"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PloS Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.4756","article-title":"Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis","volume":"33","author":"Teulings","year":"2015","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/asi.20317","article-title":"CiteSpace II: Detecting and visualizing emerging trends and transient patterns in scientific literature","volume":"57","author":"Chen","year":"2005","journal-title":"J Am Soc Inf Sci Technol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s11192-009-0146-3","article-title":"Software survey: VOSviewer, a computer program for bibliometric mapping","volume":"84","author":"van Eck","year":"2010","journal-title":"Scientometrics"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1515\/jdis-2017-0006","article-title":"Science mapping: A systematic review of the literature","volume":"2","author":"Chen","year":"2017","journal-title":"J Data Inf Sci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000001022","article-title":"Worldwide research trends on tumor burden and immunotherapy: a bibliometric analysis","volume":"110","author":"Zhang","year":"2024","journal-title":"Int J Surg"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.790125","article-title":"Janus kinase inhibitors in the treatment of vitiligo: A review","volume":"12","author":"Qi","year":"2021","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2016.11.001","article-title":"The medical treatment of vitiligo: an historical review","volume":"35","author":"Nordlund","year":"2017","journal-title":"Dermatol Clin"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e185785","DOI":"10.1172\/JCI185785","article-title":"Recent clinical and mechanistic insights into vitiligo offer new treatment options for cell-specific autoimmunity","volume":"135","author":"Ezzedine","year":"2025","journal-title":"J Clin Invest"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/asi.23437","article-title":"Comparing keywords plus of WOS and author keywords: A case study of patient adherence research","volume":"67","author":"Zhang","year":"2015","journal-title":"J Assoc Inf Sci Technol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/BF02019280","article-title":"Co-word analysis as a tool for describing the network of interactions between basic and technological research: The case of polymer chemsitry","volume":"22","author":"Callon","year":"1991","journal-title":"Scientometrics"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2024.1472337","article-title":"Mapping the intersection of sudden cardiac death and COVID-19: a comprehensive bibliometric analysis (2020-2024)","volume":"11","author":"Bhattacharya","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.5136","article-title":"Immune checkpoint inhibitor-induced vitiligo-like depigmentation","volume":"161","author":"Starace","year":"2025","journal-title":"JAMA Dermatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-023-02577-7","article-title":"Immune checkpoint inhibitor-induced vitiligo in cancer patients: characterization and management","volume":"315","author":"Lo","year":"2023","journal-title":"Arch Dermatol Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.04.045","article-title":"Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study","volume":"81","author":"Thaci","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/phpp.12740","article-title":"UVB phototherapy in the treatment of vitiligo: State of the art and clinical perspectives","volume":"38","author":"Bouceiro Mendes","year":"2022","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e2250281","DOI":"10.1002\/eji.202250281","article-title":"The IFN-gamma-CXCL9\/CXCL10-CXCR3 axis in vitiligo: Pathological mechanism and treatment","volume":"54","author":"Liu","year":"2024","journal-title":"Eur J Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2025.05.021","article-title":"Antigen-specific immune responses and microbiota interactions in skin: Insights into autoimmune skin diseases and emerging therapeutic strategies","volume":"156","author":"Takahashi","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2025.2512452","article-title":"Potential future biologic therapies for the treatment of vitiligo: focus on phase 2 and 3","volume":"21","author":"Picone","year":"2025","journal-title":"Expert Rev Clin Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad245","article-title":"Exploring the natural and treatment history of vitiligo: perceptions of patients and healthcare professionals from the global VALIANT study","volume":"189","author":"Hamzavi","year":"2023","journal-title":"Br J Dermatol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-100919-023531","article-title":"Vitiligo: mechanisms of pathogenesis and treatment","volume":"38","author":"Frisoli","year":"2020","journal-title":"Annu Rev Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1639732","article-title":"Targeting the IL-15\/CD122 signaling pathway: reversing TRM cell-mediated immune memory in vitiligo","volume":"16","author":"Su","year":"2025","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"eaau9657","DOI":"10.1126\/sciimmunol.aau9657","article-title":"Interleukin-17 receptor D constitutes an alternative receptor for interleukin-17A important in psoriasis-like skin inflammation","volume":"4","author":"Su","year":"2019","journal-title":"Sci Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2025.04.016","article-title":"Converging paths toward unified therapeutic approaches in atopic dermatitis, vitiligo, and alopecia areata","volume":"156","author":"Tordjman","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"15011","DOI":"10.1038\/nrdp.2015.11","article-title":"Vitiligo","volume":"1","author":"Picardo","year":"2015","journal-title":"Nat Rev Dis Prim"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(24)00026-4","article-title":"Estimating the burden of vitiligo: a systematic review and modelling study","volume":"9","author":"Akl","year":"2024","journal-title":"Lancet Public Health"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.4103\/ejdv.ejdv_1_23","article-title":"Study of the epidemiologic characteristics of childhood vitiligo in Egyptian children","volume":"43","author":"Aboeldahab","year":"2023","journal-title":"Egypt J Dermatol Venerol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jaad.2022.11.005","article-title":"Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial","volume":"88","author":"Ezzedine","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s11192-023-04634-4","article-title":"Exploring the clinical translation intensity of papers published by the world\u2019s top scientists in basic medicine","volume":"128","author":"Zang","year":"2023","journal-title":"Scientometrics"},{"key":"B43","doi-asserted-by":"publisher","first-page":"AB179","DOI":"10.1016\/j.jaad.2022.06.746","article-title":"34860 Levels of evidence within dermatology; bibliometric trends compared with general medicine and general surgery from 2008-2017: A bibliometric systematic review","volume":"87","author":"Ramanathan","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41572-025-00670-x","article-title":"Vitiligo","volume":"11","author":"Seneschal","year":"2025","journal-title":"Nat Rev Dis Prim"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.07.108","article-title":"The effectiveness of topical calcineurin inhibitors compared with topical corticosteroids in the treatment of vitiligo: A systematic review and meta-analysis","volume":"82","author":"Chang","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2025.2514637","article-title":"Comparative efficacy and safety of targeted narrowband ultraviolet B, 308-nm excimer laser, and 308-nm excimer lamp in vitiligo: a retrospective study","volume":"36","author":"Tantivithiwate","year":"2025","journal-title":"J Dermatolog Treat"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.16114","article-title":"Systemic therapies in vitiligo: a review","volume":"62","author":"Fatima","year":"2023","journal-title":"Int J Dermatol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17150","article-title":"Addition of oral minipulse dexamethasone to narrowband ultraviolet B phototherapy and topical steroids helps arrest disease activity in patients with vitiligo","volume":"180","author":"Tovar-Garza","year":"2019","journal-title":"Br J Dermatol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19400","article-title":"The real-life efficacy of methotrexate in vitiligo: A retrospective study and literature review","volume":"37","author":"Speeckaert","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"e15033","DOI":"10.1111\/dth.15033","article-title":"Oral cyclosporine is effective in stabilizing active vitiligo: Results of a randomized controlled trial","volume":"34","author":"Mehta","year":"2021","journal-title":"Dermatol Ther"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.5756","article-title":"Surgical interventions for patients with vitiligo: A systematic review and meta-analysis","volume":"157","author":"Ju","year":"2021","journal-title":"JAMA Dermatol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2016.11.010","article-title":"Depigmentation therapies for vitiligo","volume":"35","author":"Grimes","year":"2017","journal-title":"Dermatol Clin"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2025.11.016","article-title":"Efficacy and safety of ruxolitinib cream combined with narrow-band UVB phototherapy for treatment of vitiligo","author":"Pandya","year":"2025","journal-title":"J Invest Dermatol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.06.027","article-title":"Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib in patients with extensive vitiligo in a phase 2, randomized, double-blinded, dose-ranging, placebo-controlled study","volume":"93","author":"Pandya","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jdermsci.2023.04.006","article-title":"Targeting the elevated IFN-gamma in vitiligo patients by human anti- IFN-gamma monoclonal antibody hampers direct cytotoxicity in melanocyte","volume":"110","author":"Ng","year":"2023","journal-title":"J Dermatol Sci"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2022.06.007","article-title":"A keratinocyte-tethered biologic enables location-precise treatment in mouse vitiligo","volume":"142","author":"Hsueh","year":"2022","journal-title":"J Invest Dermatol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1111\/pcmr.13160","article-title":"Vitiligo non-responding lesions to narrow band UVB have intriguing cellular and molecular abnormalities that may prevent epidermal repigmentation","volume":"37","author":"Goldstein","year":"2024","journal-title":"Pigment Cell Melanom Res"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-016-1713-0","article-title":"Senescence in the lesional fibroblasts of non-segmental vitiligo patients","volume":"309","author":"Rani","year":"2017","journal-title":"Arch Dermatol Res"},{"key":"B59","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s00011-025-02035-2","article-title":"The IL-6 autocrine loop promoting IFN-gamma-induced fibroblast senescence is involved in psychological stress-mediated exacerbation of vitiligo","volume":"74","author":"Cao","year":"2025","journal-title":"Inflammation Res"},{"key":"B60","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jdermsci.2022.01.002","article-title":"The involvement of ERK1\/2 and p38 MAPK in the premature senescence of melanocytes induced by H(2)O(2) through a p53-independent p21 pathway","volume":"105","author":"Hou","year":"2022","journal-title":"J Dermatol Sci"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2020.108670","article-title":"Nuclear factor erythroid 2-related factor 2 (Nrf2) as a potential therapeutic target for vitiligo","volume":"696","author":"Lin","year":"2020","journal-title":"Arch Biochem Biophys"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2025.102686","article-title":"Senescence as a molecular target in skin aging and disease","volume":"105","author":"Thau","year":"2025","journal-title":"Ageing Res Rev"},{"key":"B63","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.3390\/biomedicines10112744","article-title":"Regenerative medicine-based treatment for vitiligo: an overview","volume":"10","author":"Bellei","year":"2022","journal-title":"Biomedicines"},{"key":"B64","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1080\/09205063.2025.2511991","article-title":"Budding trends in nanofibers for topical delivery of therapeutics for the treatment of vitiligo","volume":"36","author":"Nagendra Yadav","year":"2025","journal-title":"J Biomater Sci Polym Ed"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.14691","article-title":"Treatment of stable nonsegmental vitiligo using transdermal delivery of 5-fluorouracil by fractional CO(2) laser versus intralesional injection of 5-fluorouracil, both followed by narrow-band type ultraviolet B (UVB): A comparative study","volume":"21","author":"Elgarhy","year":"2022","journal-title":"J Cosmet Dermatol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2022.04.019","article-title":"RNAi-based modulation of IFN-gamma signaling in skin","volume":"30","author":"Tang","year":"2022","journal-title":"Mol Ther"},{"key":"B67","doi-asserted-by":"publisher","first-page":"7099","DOI":"10.1038\/s41467-023-42714-4","article-title":"Rational design of a JAK1-selective siRNA inhibitor for the modulation of autoimmunity in the skin","volume":"14","author":"Tang","year":"2023","journal-title":"Nat Commun"},{"key":"B68","doi-asserted-by":"publisher","first-page":"btae672","DOI":"10.1093\/bioinformatics\/btae672","article-title":"PubMed Computed Authors in 2024: an open resource of disambiguated author names in biomedical literature","volume":"40","author":"Tian","year":"2024","journal-title":"Bioinformatics"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.2147\/JMDH.S517583","article-title":"A comprehensive bibliometric analysis of brucellosis research: insights from CNKI and web of science databases (2014-2023)","volume":"18","author":"Wang","year":"2025","journal-title":"J Multidiscip Healthc"},{"key":"B70","doi-asserted-by":"publisher","first-page":"e00197820","DOI":"10.1590\/0102-311X00197820","article-title":"Trends in general and public health scientific output of authors affiliated to Brazilian institutions among high-impact and SciELO journals: 1995-2019","volume":"37","author":"Celeste","year":"2021","journal-title":"Cad Saude Public"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1733857\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T06:41:21Z","timestamp":1768372881000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1733857\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":70,"alternative-id":["10.3389\/fimmu.2025.1733857"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1733857","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"article-number":"1733857"}}